Voya Financial Advisors Inc. Sells 143 Shares of Becton, Dickinson and Company (NYSE:BDX)


Share on StockTwits

Voya Financial Advisors Inc. lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.4% in the fourth quarter, Holdings Channel reports. The firm owned 4,088 shares of the medical instruments supplier’s stock after selling 143 shares during the period. Voya Financial Advisors Inc.’s holdings in Becton, Dickinson and were worth $1,009,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the business. Alpha Omega Wealth Management LLC boosted its position in Becton, Dickinson and by 0.6% during the fourth quarter. Alpha Omega Wealth Management LLC now owns 8,004 shares of the medical instruments supplier’s stock worth $2,003,000 after purchasing an additional 44 shares during the period. Verdence Capital Advisors LLC boosted its position in Becton, Dickinson and by 1.8% during the fourth quarter. Verdence Capital Advisors LLC now owns 2,572 shares of the medical instruments supplier’s stock worth $644,000 after purchasing an additional 45 shares during the period. Valeo Financial Advisors LLC boosted its position in Becton, Dickinson and by 3.6% during the fourth quarter. Valeo Financial Advisors LLC now owns 1,350 shares of the medical instruments supplier’s stock worth $338,000 after purchasing an additional 47 shares during the period. Central Bank & Trust Co. boosted its position in Becton, Dickinson and by 2.4% during the fourth quarter. Central Bank & Trust Co. now owns 2,048 shares of the medical instruments supplier’s stock worth $512,000 after purchasing an additional 48 shares during the period. Finally, IFP Advisors Inc boosted its position in Becton, Dickinson and by 1.3% during the fourth quarter. IFP Advisors Inc now owns 3,883 shares of the medical instruments supplier’s stock worth $977,000 after purchasing an additional 48 shares during the period. 83.22% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on BDX shares. Piper Sandler increased their price objective on Becton, Dickinson and from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 4th. The Goldman Sachs Group cut Becton, Dickinson and from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, December 15th. TheStreet raised Becton, Dickinson and from a “c+” rating to an “a-” rating in a research report on Thursday, February 4th. Morgan Stanley raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $262.00 to $297.00 in a research report on Tuesday, December 15th. Finally, Raymond James raised their target price on Becton, Dickinson and from $270.00 to $282.00 and gave the stock an “outperform” rating in a research report on Friday, January 29th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Becton, Dickinson and has an average rating of “Buy” and a consensus target price of $281.08.

Becton, Dickinson and stock opened at $244.02 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.54 and a quick ratio of 1.07. The stock has a fifty day moving average price of $243.71 and a two-hundred day moving average price of $243.60. Becton, Dickinson and Company has a 52-week low of $219.50 and a 52-week high of $284.97. The firm has a market capitalization of $70.90 billion, a P/E ratio of 89.38, a P/E/G ratio of 2.34 and a beta of 0.79.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.14 by $1.41. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The company had revenue of $5.32 billion during the quarter, compared to analyst estimates of $4.87 billion. During the same period last year, the company posted $2.65 earnings per share. The firm’s quarterly revenue was up 25.8% compared to the same quarter last year. On average, equities research analysts predict that Becton, Dickinson and Company will post 12.5 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 31st. Stockholders of record on Wednesday, March 10th were paid a $0.83 dividend. The ex-dividend date was Tuesday, March 9th. This represents a $3.32 dividend on an annualized basis and a dividend yield of 1.36%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 32.55%.

Becton, Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: What does a market perform rating mean?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.